Search

Your search keyword '"Furuse, Junji"' showing total 47 results
Start Over Author "Furuse, Junji" Publisher oxford university press / usa
47 results on '"Furuse, Junji"'

3. Protocol of a randomized phase II/III study of gemcitabine plus nab-paclitaxel combination therapy versus modified FOLFIRINOX versus S-IROX for metastatic or recurrent pancreatic cancer: JCOG1611 (GENERATE).

Author

Mizusawa, Junki, Ohba, Akihiro, Ozaka, Masato, Katayama, Hiroshi, Okusaka, Takuji, Kobayashi, Satoshi, Ikeda, Masafumi, Terashima, Takeshi, Sasahira, Naoki, Okano, Naohiro, Miki, Ikuya, Kaneko, Takashi, Mizuno, Nobumasa, Todaka, Akiko, Furukawa, Masayuki, Kajiura, Shinya, Kataoka, Tomoko, Fukuda, Haruhiko, Furuse, Junji, and Ueno, Makoto

Published
2023
Full Text
View/download PDF

8. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106.

Author

Ioka, Tatsuya, Furuse, Junji, Fukutomi, Akira, Mizusawa, Junki, Nakamura, Satoaki, Hiraoka, Nobuyoshi, Ito, Yoshinori, Katayama, Hiroshi, Ueno, Makoto, Ikeda, Masafumi, Sugimori, Kazuya, Okano, Naohiro, Shimizu, Kyoko, Yanagimoto, Hiroaki, Okusaka, Takuji, Ozaka, Masato, Todaka, Akiko, Nakamori, Shoji, Tobimatsu, Kazutoshi, and Sata, Naohiro

Published
2021
Full Text
View/download PDF

12. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).

Author

Motoi, Fuyuhiko, Kosuge, Tomoo, Ueno, Hideki, Yamaue, Hiroki, Satoi, Sohei, Sho, Masayuki, Honda, Goro, Matsumoto, Ippei, Wada, Keita, Furuse, Junji, Matsuyama, Yutaka, Unno, Michiaki, and (JSAP), Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer

Published
2019
Full Text
View/download PDF

16. High-Resolution Computed Tomography Findings for Patients With Drug-Induced Pulmonary Toxicity, With Special Reference to Hypersensitivity Pneumonitis-Like Patterns in Gemcitabine-Induced Cases.

Author

Tamura, Masaki, Saraya, Takeshi, Fujiwara, Masachika, Hiraoka, Sayuki, Yokoyama, Takuma, Yano, Kinuko, Ishii, Haruyuki, Furuse, Junji, Goya, Tomoyuki, Takizawa, Hajime, and Goto, Hajime

Subjects
TOMOGRAPHY, ACADEMIC medical centers, ANTIMETABOLITES, ANTINEOPLASTIC agents, CHI-squared test, DRUG toxicity, HYPERSENSITIVITY pneumonitis, LUNG diseases, U-statistics, RETROSPECTIVE studies, DATA analysis software, DESCRIPTIVE statistics
Abstract

Background. Gemcitabine (GEM) is widely used as a chemotherapeutic agent. However, pulmonary toxicity has been rarely observed with GEM use. This article aims to determine the incidence and causes of drug-induced pulmonary toxicity, and to classify the high-resolution computed tomography (HRCT) findings for antitumor therapy-associated pulmonary toxicity based on characteristic patterns and pathological considerations, with a special focus on GEM-associated pulmonary toxicity (GAPT). Methods. Medical records of all patients with drug-induced pulmonary toxicity seen at Kyorin University hospital between April 2006 and December 2011 were retrospectively reviewed. The study examined correlations between HRCT and the assessed pathological or clinical findings, with a specific focus on antitumor drugs. Results. We identified 66 patients with drug-induced pulmonary toxicity. Among the antitumor drugs, GEM was the primary offending agent (n = 8) for pulmonary toxicity followed by docetaxel and gefitinib. HRCT patterns for the eight GAPT patients included the non-specific interstitial pneumonia (NSIP; n = 5) and the hypersensitivity pneumonitis (HP)-like pattern (n = 3). In contrast, four patients in the study were found to have the HP-like pattern, with three cases associated with GEM and one case associated with imatinib mesylate. The transbronchial lung biopsy or video-assisted thoracic surgery specimens for these patients showed granuloma or organizing tissue with a random distribution that was independent of the respiratory bronchiole. These results appeared to correspond to the HRCT-determined centrilobular nodules. Conclusion. GEM was the leading cause of drug-induced pulmonary toxicity in the patients examined in this study. This toxicity appears as NSIP or an HP-like pattern during HRCT examinations. This HP-like pattern may be useful for diagnosing GEM-induced pulmonary toxicity, as well as demonstrating granuloma or organizing tissue during lung pathology examinations. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

22. The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective.

Author

Venook, Alan P., Papandreou, Christos, Furuse, Junji, and Ladrón de Guevara, Laura

Subjects
HEPATITIS B, HEPATITIS C, HEPATOCELLULAR carcinoma, POPULATION geography, WORLD health, DISEASE incidence
Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and the burden of this devastating cancer is expected to increase further in coming years. The collection and analysis of epidemiologic HCC data will play a critical role in guiding future disease prevention strategies and optimizing patient management. Previous epidemiologic studies have highlighted striking global variations in the incidence of HCC, which is particularly high in much of east Asia and sub-Saharan Africa, and lower, but on the increase, in North America and most of Europe. This variation appears to be related to the complex etiology of HCC, with different risk factors, primarily infection with hepatitis B or hepatitis C virus, responsible for driving HCC incidence rates in different regions. Although previous studies have contributed considerably to the knowledge of HCC epidemiology, there are limitations associated with the currently available data, which arise from studies performed at different times in the past, using varying methodologies, and with diverse patient populations. A new and global approach to the study of HCC epidemiology is required if HCC disease prevention and treatment strategies are to be adequately directed and supported in coming years. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

23. The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective.

Author

VENOOK, ALAN P., PAPANDREOU, CHRISTOS, FURUSE, JUNJI, and DE GUEVARA, LAURA LADRàN

Subjects
HEPATOCELLULAR carcinoma, POPULATION geography, DISEASE incidence
Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and the burden of this devastating cancer is expected to increase further in coming years. The collection and analysis of epidemiologic HCC data will play a critical role in guiding future disease prevention strategies and optimizing patient management. Previous epidemiologic studies have highlighted striking global variations in the incidence of HCC, which is particularly high in much of east Asia and sub-Saharan Africa, and lower, but on the increase, in North America and most of Europe. This variation appears to be related to the complex etiology of HCC, with different risk factors, primarily infection with hepatitis B or hepatitis C virus, responsible for driving HCC incidence rates in different regions. Although previous studies have contributed considerably to the knowledge of HCC epidemiology, there are limitations associated with the currently available data, which arise from studies performed at different times in the past, using varying methodologies, and with diverse patient populations.A new and global approach to the study of HCC epidemiology is required if HCC disease prevention and treatment strategies are to be adequately directed and supported in coming years. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

37. Phase I Trial of Gemcitabine in Patients with Advanced Pancreatic Cancer.

Author

Okada, Shuichi, Ueno, Hideki, Okusaka, Takuji, Ikeda, Masafumi, Furuse, Junji, and Maru, Yasushi

Abstract

Evaluates the tolerability of a weekly schedule of gemcitabine at a dose of 1000 mg/m[sup 2] in Japanese patients with advanced pancreatic cancer. Chemotherapeutic agents; Dose-limiting toxicity of the drug; drug side-effects.

Published
2001
Full Text
View/download PDF

45. Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine‐Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX‐BC Study).

Author

Okano, Naohiro, Furuse, Junji, Ueno, Makoto, Morizane, Chigusa, Yamanaka, Takeharu, Ojima, Hidenori, Ozaka, Masato, Sasaki, Mitsuhito, Takahara, Naminatsu, Nakai, Yousuke, Kobayashi, Satoshi, Morimoto, Manabu, Hosoi, Hiroko, Maeno, Satoko, Nagashima, Fumio, Ikeda, Masafumi, and Okusaka, Takuji

Subjects
THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of antimetabolites, ANTINEOPLASTIC agents, ASCITES, BENZAMIDE, CANCER chemotherapy, CANCER patients, CELL receptors, CLINICAL trials, CONFIDENCE intervals, DRUG resistance in cancer cells, DRUG efficacy, MEDICAL cooperation, ORAL drug administration, RESEARCH, SURVIVAL analysis (Biometry), TUMOR markers, BILE duct tumors, PROTEIN-tyrosine kinase inhibitors, ENDOTHELIAL growth factors, DESCRIPTIVE statistics, EVALUATION
Abstract

Lessons Learned: Axitinib exhibited marginal activity against gemcitabine‐refractory unselected biliary tract cancer.Pretreated soluble vascular endothelial growth factor receptor‐2 may be a useful biomarker for axitinib treatment outcome.Ascites should be carefully monitored in patients receiving anti–vascular endothelial growth factor receptor therapy including axitinib in advanced biliary tract cancer. Background: There are no clear options for second‐line treatment in patients with gemcitabine (GEM)‐refractory biliary tract cancer (BTC). We conducted a multicenter, single‐arm, phase II trial to confirm the efficacy and safety of axitinib, a potent selective inhibitor of vascular endothelial growth factor receptor (VEGFR)‐1/2/3, in patients with GEM‐refractory BTC. Methods: Patients refractory or intolerant to GEM‐based chemotherapy were enrolled. Axitinib was administered orally at an initial dose of 5 mg twice daily. The primary endpoint was progression‐free survival (PFS), and the threshold and expected values were set at 2 and 3 months, respectively. The target sample size was 32 patients. Results: Nineteen patients were enrolled. The trial was interrupted for a total of 13 months for the evaluation of adverse events. Thirteen patients were previously treated with ≥2 regimens. The median PFS was 2.8 months (95% confidence interval [CI]: 2.1–4.1). The median overall survival was 5.8 months (95% CI: 3.3–9.7). The response rate was 5.3% (95% CI: 0.0–15.3). Grade 3 ascites occurred in two patients. Baseline soluble VEGFR‐2 levels were significantly associated with PFS. Conclusion: Axitinib exhibited marginal activity against GEM‐refractory BTC. Ascites should be carefully monitored in axitinib‐treated patients with advanced BTC. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

47. Liver Cancer Working Group Report.

Author

Kudo, Masatoshi, Han, Kwang Hyub, Kokudo, Norihiro, Cheng, Ann-Lii, Choi, Byung Ihn, Furuse, Junji, Izumi, Namiki, Park, Joong-Won, Poon, Ronnie T., and Sakamoto, Michiie

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results